Plasma p-tau181 (Phosphorylated Tau at Threonine 181)

Overview

Phosphorylated tau at threonine 181 (p-tau181) is a highly specific blood-based biomarker for Alzheimer's disease pathology. It was one of the first phosphorylated tau species to be developed as a plasma assay and remains widely used in clinical research and increasingly in clinical practice. Plasma p-tau181 correlates with both amyloid-beta and tau pathology as measured by PET imaging, making it a valuable biomarker for detecting Alzheimer-type neurodegeneration.[@palmqvist2020][@janelidze2021]

Pathophysiology

```mermaid
flowchart TD
%% Blue = Triggers/Inputs
A["Amyloid-beta<br/>Oligomers"]:::blue

%% Orange = Intermediate steps
B["Kinase Activation<br/>GSK-3beta, CDK5, PKA"]:::orange

%% Red = Pathological events
C["Tau Hyperphosphorylation<br/>at Threonine 181"]:::red

%% Purple = Therapeutic targets
D["Neurofibrillary Tangle<br/>Formation"]:::purple

%% Yellow = Decision points
E["Neuronal Damage<br/>and Axonal Degeneration"]:::yellow

%% Blue = Outputs
F["CSF p-tau181<br/>Elevated"]:::blue

G["Blood-Brain<br/>Barrier"]:::blue

H["Blood p-tau181<br/>Elevated"]:::blue

I{"Diagnostic Interpretation"}:::yellow

J["AD Pathology<br/>Likely"]:::green

K["Consider Non-AD<br/>Etiology"]:::green

L["Systemic<br/>Amyloidosis?"]:::yellow

M["Clinical Diagnosis<br/>AD Supported"]:::green

N["Differential<br/>Diagnosis Workup"]:::blue

O["Additional<br/>Testing"]:::blue

Overview

Phosphorylated tau at threonine 181 (p-tau181) is a highly specific blood-based biomarker for Alzheimer's disease pathology. It was one of the first phosphorylated tau species to be developed as a plasma assay and remains widely used in clinical research and increasingly in clinical practice. Plasma p-tau181 correlates with both amyloid-beta and tau pathology as measured by PET imaging, making it a valuable biomarker for detecting Alzheimer-type neurodegeneration.[@palmqvist2020][@janelidze2021]

Pathophysiology

Biological Function

Tau Phosphorylation at Threonine 181

The tau protein (encoded by the MAPT gene) is a microtubule-associated protein that stabilizes neuronal axons. In Alzheimer's disease, tau becomes abnormally hyperphosphorylated, leading to neurofibrillary tangle formation. Threonine 181 is one of the earliest and most studied phosphorylation sites on tau.[@palmqvist2020]

The phosphorylation at position 181 occurs via several kinases, including:

• GSK-3β (glycogen synthase kinase-3 beta)
• CDK5 (cyclin-dependent kinase 5)
• PKA (protein kinase A)

Release into Blood

p-tau181 is released into the cerebrospinal fluid (CSF) and subsequently into blood through:

The phosphorylated form (p-tau181) appears to be more specific to AD pathology than total tau, as it reflects the disease-specific post-translational modifications occurring in AD brains.[@palmqvist2020][@janelidze2021]

Clinical Utility

Alzheimer's Disease Detection

Plasma p-tau181 has demonstrated excellent performance for distinguishing Alzheimer's disease from:

• Healthy controls
• Other dementias (frontotemporal dementia, vascular dementia)
• Other neurodegenerative disorders (Parkinson's disease, Lewy body dementia)

• AUC: 0.85-0.95 for AD vs. controls
• Sensitivity: 80-90%
• Specificity: 85-95%

Mild Cognitive Impairment (MCI) Prediction

p-tau181 is particularly valuable for predicting progression from MCI to AD dementia:

• Elevated p-tau181 in MCI patients predicts progression to AD with high accuracy
• Combines well with amyloid-beta 42/40 ratio for enhanced prediction
• Can identify AD pathology years before clinical dementia onset

Amyloid and Tau PET Correlation

Plasma p-tau181 correlates with:

• Amyloid PET burden (moderate correlation)
• Tau PET burden (stronger correlation)
• CSF p-tau181 levels (strong correlation)

Detection Methods

FDA-Approved/EU-Certified Platforms

• Fully automated chemiluminescence enzyme immunoassay (CLEIA)
• FDA-approved for CSF p-tau181 (Lumipulse G Tau)
• Plasma version available in Europe
• High precision and reproducibility

• Electrochemiluminescence immunoassay (ECLIA)
• Available for both CSF and plasma
• Automated platform with high throughput

Research Use Only Platforms

• Single molecule array (Simoa) technology
• Ultra-sensitive detection
• Most widely used in research settings
• Allows detection of very low concentrations in plasma

• Third-generation immunochemiluminometric assay
• Higher sensitivity than previous generations
• Improved precision

• Mass spectrometry-based quantification
• High specificity for specific tau phospho-forms

Comparison to Other Tau Biomarkers

| Biomarker | Specificity | Sensitivity (AD) | CSF/Plasma | Key Advantage |
|-----------|-------------|------------------|------------|---------------|
| p-tau181 | High | 85-90% | Both | First validated, widely available |
| p-tau217 | Very High | 90-95% | Both | Best for differential diagnosis |
| p-tau231 | High | 80-85% | CSF only | Earliest detection in preclinical AD |
| Total tau | Moderate | 70-80% | Both | Non-specific neuronal damage |

p-tau181 vs p-tau217

• p-tau217 shows slightly better performance for distinguishing AD from other neurodegenerative diseases
• p-tau181 was the first to be widely validated and has more established clinical data
• Both correlate well with tau PET and predict cognitive decline
• p-tau217 may be slightly better for detecting early/mild AD

p-tau181 in Non-AD Conditions

Recent research (2026) has revealed that p-tau181 can also be elevated in systemic amyloidoses:[@elevated2026]

• Immunoglobulin light chain (AL) amyloidosis: ~2.5x elevated
• Transthyretin (ATTR) amyloidosis: ~2.5x elevated

p-tau181 in 4R Tauopathies

Corticobasal Degeneration (CBD)

In corticobasal syndrome (CBS), plasma p-tau181 helps distinguish:[@altmann2025][@stamelou2023]

• CBS due to CBD: p-tau181 typically normal or mildly elevated
• CBS due to AD: p-tau181 markedly elevated, similar to AD levels

Progressive Supranuclear Palsy (PSP)

In PSP, p-tau181 shows:

• Mild to moderate elevation compared to healthy controls
• Lower levels than AD but higher than Parkinson's disease
• When combined with NfL, can help distinguish PSP from other parkinsonisms

Clinical Implementation

Interpretation Guidelines

p-tau181 should be interpreted in clinical context:

• Elevated p-tau181 + clinical symptoms → supports AD diagnosis
• Normal p-tau181 + clinical symptoms → consider non-AD etiology
• Elevated p-tau181 + negative amyloid → consider alternative diagnoses (systemic amyloidosis)

ATN Framework Integration

p-tau181 serves as the T (tau) biomarker in the ATN (Amyloid/Tau/Neurodegeneration) research framework:

• A+ (Amyloid positive): Aβ42/40 ratio, amyloid PET
• T+ (Tau positive): p-tau181, p-tau217, tau PET
• N+ (Neurodegeneration): NfL, FDG-PET, MRI atrophy
• Tau Pathology Pathway
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• Amyloid-beta Biomarkers
• Blood Biomarkers for Neurodegeneration
• CSF Biomarkers Comparison
• p-tau217
• Neurofilament Light Chain (NfL)

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[DOI:10.1001/jama.2020.12134](https://doi.org/10.1001/jamaneurol.2021.3180)
[DOI:10.1016/S1474-4422(22](22])